generics
-
First floor
generics. World pharmaceutical production is mostly in China and India and is a problem for Western health authorities
The historic record of drug withdrawals in Spain took place in 2018. Why? More than a hundred…
Leggi » -
News
US China trade war. The secret weapon in the hands of Beijing are medicines: they control the 40% of the active ingredients of American generic drugs
China compensates for the 40% of the active ingredients (APIs) present in American drugs and the 80% of the ingredients used by India, the first…
Leggi » -
News
Medicines. Therapeutic equivalence, the State Council promotes Puglia
Il Consiglio di Stato boccia la sentenza del TAR Puglia e dà ragione alla Regione Puglia sull’utilizzo dei farmici in…
Leggi » -
News
Generic drugs: Italians European champions for knowledge but not for use
“Gli italiani conoscono molto bene il sistema dei farmaci equivalenti, cosa che non trova riscontro in altri Paesi” MeteoWeb – 16…
Leggi » -
First floor
Swiss. There is a lack of patent-expired drugs. Branded companies are no longer convenient and China, which produces generics for the whole world, is unable to meet the demands
There is a shortage of (certain) medicines in Switzerland Swiss TV – 10 June 2019 In Switzerland, home to some of the…
Leggi » -
First floor
Swiss. Consumers are asking for the origin of the drug to be indicated on generic packaging
“Perché non ci dite l’origine dei farmaci?” La Svizzera chiama in causa Big Pharma Il Salvagente – 13 maggio 2019…
Leggi » -
First floor
USA. Teva and nineteen other generic pharmaceutical companies accused of rigging the price fixing system
WASHINGTON (Reuters) - The United States has filed a lawsuit accusing 20 drug companies of generics, including Teva…
Leggi » -
News
Great Pharma War: India criticizes US crusade against cheap generic drugs
La spinta di Washington per i diritti di proprietà intellettuale nell’industria farmaceutica è un attacco all’industria farmaceutica indiana, secondo New…
Leggi » -
First floor
Price of medicines: a reply to the Director of AIFA. With the fetish of transparency, the hedging difficulties of a State with delusions of omnipotence are unloaded on the sector
The medicines market is heavily regulated. Even before some specific strategies to contain pharmaceutical expenditure, such as…
Leggi » -
News
Tuscany Regional Administrative Court. Biologics and biosimilars are not identical. Automatic substitution is not allowed. Regional Resolution 194: excess of power and incompetence
Ancora una volta l’oggetto del contenzioso sono farmaci biologici e l’orientamento delle scelte prescrittive. I giudici accolgono il rilievo di…
Leggi »